Cite
HARVARD Citation
Khalaf, D. et al. (2019). Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet oncology. 20 (12), pp. 1730-1739. [Online].